We further examined the association of MUC16 mutation with outcomes in 2 ICI-treated cohorts, comprising 1 NSCLC cohort with 56 patients (median [IQR] age, 61 [57-66] years; 24 men [43%]) and 1 melanoma cohort with 145 patients (median [IQR] age, 61 [47-71] years; 98 men [67.6%]). This evidence concerns the gene MUC16 and non-small cell lung carcinoma.